Raia Drogasil (RADLY) Set to Release Quarterly Earnings on Tuesday

Key Points

• Raia Drogasil is expected to report quarterly results after Tuesday’s market close, with analysts projecting $0.05 in earnings per share and $2.41 billion in revenue.
• The company previously matched consensus earnings at $0.05 per share but missed revenue estimates, reporting $2.17 billion versus $2.32 billion expected.
• The stock has fallen 5% to $2.85 and is near its 12-month low, although analysts maintain a “Moderate Buy” consensus rating with a $5.20 average price target.

Raia Drogasil (OTCMKTS:RADLY - Get Free Report) is expected to announce its results after the market closes on Tuesday, November 3rd. Analysts expect the company to post earnings of $0.05 per share and revenue of $2.41 billion for the quarter.

Raia Drogasil (OTCMKTS:RADLY - Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The company reported $0.05 earnings per share for the quarter, hitting analysts' consensus estimates of $0.05. Raia Drogasil had a net margin of 2.99% and a return on equity of 20.12%. The company had revenue of $2.17 billion during the quarter, compared to analyst estimates of $2.32 billion. On average, analysts expect Raia Drogasil to post $0.17 EPS for the current fiscal year and $0.24 EPS for the next fiscal year.

Raia Drogasil Stock Down 5.0%

RADLY traded down $0.15 during trading on Tuesday, hitting $2.85. 187,774 shares of the company's stock traded hands, compared to its average volume of 180,914. The company's 50 day simple moving average is $3.80 and its two-hundred day simple moving average is $4.12. The company has a current ratio of 1.41, a quick ratio of 0.58 and a debt-to-equity ratio of 0.99. Raia Drogasil has a 12-month low of $2.80 and a 12-month high of $5.34. The stock has a market capitalization of $3.75 billion and a price-to-earnings ratio of 19.00.

Wall Street Analyst Weigh In

Separately, Jefferies Financial Group raised Raia Drogasil to a "buy" rating and set a $5.20 price target on the stock in a report on Sunday, October 18th. One analyst has rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $5.20.

Raia Drogasil Company Profile

Raia Drogasil, now operating under the name RD Saúde, is a Brazilian healthcare and pharmacy retail company. It operates a network of pharmacies offering prescription medicines, over-the-counter drugs, vitamins, personal care products, beauty items and other health-related merchandise.

The company also provides digital purchasing and delivery services through its online channels, supporting customers with prescription fulfillment, health products and related services. Its operations include pharmacy-based healthcare initiatives designed to complement its retail business and improve access to everyday healthcare.

RD Saúde was created in 2011 through the merger of Drogasil and Droga Raia, two established Brazilian pharmacy chains.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.